Sawai Pharmaceutical Forms Strategic Alliance with Sumitomo Corp
in the US Generics Market
Building a Global Trusted Generics Company[November 13, 2017, Tokyo] Sawai Pharmaceutical Co. Ltd. (“Sawai”), a leading Japanese generic drug
manufacturer, announced today to sell a 20% stake in its US subsidiary, SAWAI AMERICA INC. (“SAI”), theparent company of Upsher‐Smith Laboratories, LLC (“USL”), the U.S. generics drug company Sawai acquired
earlier this year, to Sumitomo Corporation of Americas (“SCOA”), a subsidiary of Sumitomo Corporation(“SC”), one of Japan’s leading general trading houses (”Transaction”). Through this investment, Sawai andSC formed a strategic alliance in the generic pharmaceuticals business in the US.
Under the agreement signed today, SAI will first be transformed into a Limited Liability Company (LLC) andrenamed to SAWAI AMERICA, LLC (“SAL”) and then SCOA will acquire a 20% stake in SAL. Sawai will alsoestablish SAWAI AMERICA HOLDINGS INC., the interim holding company in the U.S., which will be theparent company of SAL by the time the Transaction is executed.
SCOA will acquire the stake for consideration of $211 million. This consideration will be adjusted reflecting
the profit yielded by USL during the period between Sawai’s acquisition of USL and closing of theTransaction. The Transaction is expected to close by the end of March 2018.
Sawai has been expanding the generic drug business in Japan in order to respond to the policy agenda
advocated by the Government of Japan to increase the market share of generic prescriptions to 80% in
terms of volume. Sawai also aims to strengthen its global business network, as stipulated in its Medium‐term Business Plan, to achieve further growth moving forward. In June 2017, Sawai acquired USL and madea full scale entry into U.S., the world’s largest generic pharmaceuticals market.
SC is a major organizer of multinational projects, an expediter of ideas, an important international investor
and financier, and a powerful force for distribution of products and global communications through anetwork of offices worldwide. Its core business units include Tubular Products, Environment andInfrastructure, Steel and Non Ferrous Metals, Transportation and Construction Systems, Chemicals andElectronics, Media and IOT Applications, Real Estate, Mineral Resources and Energy, and Food.
“SC’s investment in SAI and their management participation in USL will facilitate to leverage SC’sexperience, knowledge and network in the global business arena in such areas as sourcing of active
pharmaceutical ingredients (APIs) and product introduction” said Mitsuo Sawai, President of Sawai. “Wewill continue to enhance our global presence including the U.S. business to accelerate growth with our goal
to become “a Globally Recognized Generics Company” by leveraging the strengths and uniqueness of thethree companies, namely Sawai, USL and Sumitomo Corp.”
SAI will continue to be a consolidated subsidiary of Sawai. No change is planned for performance forecast.

‐Ends‐1|PageAbout Sawai Pharmaceuticals Co., Ltd.
Founded in 1929, Sawai Pharmaceutical Co., Ltd. has grown into one of the leading generics companies in Japan.
Guided by its corporate philosophy, “Patients First,” Sawai markets more than 700 high‐quality generic products andreliably delivers them to patients throughout Japan. In 2017, Sawai acquired US‐based Upsher‐Smith Laboratories, LLC
marking its first step in overseas expansion to become a globally recognized generic pharmaceutical company.
For more information, visit : https://www.sawai.co.jp/en/

About Sumitomo Corporation
Sumitomo Corporation is a leading Fortune 500 global trading and business investment company with 107 locations in65 countries and 22 locations in Japan. The entire SC Group consists of more than 800 companies and nearly 70,000
personnel. SC conducts commodity transactions in all industries utilizing worldwide networks, provides related
customers with various financing, serves as an organizer and a coordinator for various projects, and invests incompanies to promote greater growth potential. SC’s core business areas include Metal Products, Transportation andConstruction Systems, Environment and Infrastructure, Media, Network, Lifestyle Related Goods and Services,
Mineral Resources, Energy, and Chemical and Electronics. For more information, please visit:
http://www.sumitomocorp.co.jp/english/

About Upsher‐Smith Laboratories, LLC
Upsher‐Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that has strived to deliver quality,
affordable generic medications for nearly a century. In June 2017, Upsher‐Smith was acquired by Sawai
Pharmaceutical Co., Ltd., a large publicly traded generics company in Japan that had been seeking entry into the U.S.
market. Upsher‐Smith and Sawai share a strikingly similar family history and hold many of the same cherished goals
and values—most importantly, the philosophy of always putting patients first.
Upsher‐Smith will continue to do those things it does best, which is provide a consistent supply of quality, affordable
medications and invest in its historically strong industry relationships. Ultimately, Upsher‐Smith believes theacquisition by Sawai represents a tremendous opportunity to leverage each other for growth worldwide and embark
together on an exciting new chapter in generics. For more information, visit www.upsher‐smith.com.

2|Page